文献速递慢性肾脏病肾血管病与高血压

将新强化血压分类应用于非透析慢性肾脏病人群:中国高血压慢性肾脏病患者患病率、知晓率和治疗率调查

Applying the new intensive blood pressure categories to a nondialysis chronic kidney disease population: the Prevalence, Awareness and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China survey.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

本研究为全国多中心横断面研究,纳入中国31个省份61家三级医院的8927例非透析慢性肾脏病(CKD)患者,采用2017年ACC/AHA血压分类评估高血压患病率、知晓率、治疗率及控制情况。结果显示高血压患病率79.8%、知晓率72.4%、治疗率68.3%,仅11.9%患者血压<130/80 mmHg;多因素调整后仅2级高血压与肾功能下降、心血管疾病和脑血管疾病相关。结论提示新定义下非透析CKD患者高血压患病率高、控制率低,新分类的适用性仍需更多研究确认。

要点

  • 非透析CKD患者高血压患病率79.8%、知晓率72.4%、治疗率68.3%。
  • 仅11.9%患者血压<130/80 mmHg,6.6%患者血压<120/80 mmHg。
  • 仅2级高血压与肾功能下降、心血管及脑血管疾病独立相关。

核心结论

  • 采用2017年ACC/AHA新血压分类,非透析CKD患者高血压患病率更高、控制率更低。
  • 仅2级高血压与主要靶器官损伤(肾功能下降、心血管疾病、脑血管疾病)存在统计学关联。
  • 新血压分类在CKD人群中的适用性尚需更多研究证实。

研究设计与样本

  • 全国多中心、大样本横断面研究,纳入中国31个省份61家三级医院的8927例非透析CKD患者。
  • 血压分类定义:正常血压<120/80 mmHg;血压升高为收缩压120-130 mmHg且舒张压<80 mmHg;1级高血压为收缩压130-139 mmHg或舒张压80-89 mmHg;2级高血压为收缩压≥140 mmHg或舒张压≥90 mmHg。
  • 分析高血压患病率、知晓率、治疗率及控制情况,并分析主要靶器官损伤与新血压分类的关联。

主要发现

  • 非透析CKD患者高血压患病率为79.8%,知晓率为72.4%,治疗率为68.3%。
  • 约11.9%的患者血压<130/80 mmHg,6.6%的患者血压<120/80 mmHg。
  • 不同血压分类亚组在年龄、性别、体重指数分类、原发病因和CKD分期上差异有统计学意义(P < 0.001)。
  • 多因素调整后,仅2级高血压与肾功能下降相关(OR 2.4,95% CI 1.9-3.0,P < 0.001)。
  • 多因素调整后,仅2级高血压与心血管疾病相关(OR 2.0,95% CI 1.3-3.1,P = 0.001),与脑血管疾病相关(OR 2.7,95% CI 1.2-5.8,P = 0.015)。

关键数值与推荐

  • 高血压新分类标准:正常血压<120/80 mmHg;血压升高为收缩压120-130 mmHg且舒张压<80 mmHg;1级高血压为收缩压130-139 mmHg或舒张压80-89 mmHg;2级高血压为收缩压≥140 mmHg或舒张压≥90 mmHg。

临床怎么用

  • 在非透析CKD人群中,应关注新血压分类下高血压的高患病率和低控制率。
  • 2级高血压与肾功能下降、心血管疾病和脑血管疾病独立相关,提示该人群需积极控制血压至2级以下。
  • 新血压分类中1级高血压与靶器官损伤的关联未达统计学意义,临床决策时需结合个体情况。

局限性

  • 横断面设计无法推断因果关系。
  • 仅2级高血压显示与靶器官损伤的统计学关联,新分类在CKD人群的适用性需更多研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2017 high blood pressure (BP) clinical practice guideline reported by the American College of Cardiology/American Heart Association put forward new categories of BP. This study aimed to assess the applicability of the new guideline in a nondialysis chronic kidney disease (CKD) population. METHODS: This is a nationwide, multicenter, cross-sectional study with a large sample. A total of 8927 nondialysis CKD patients in 61 tertiary hospitals in all 31 provinces, municipalities and autonomous regions of China (except Hong Kong, Macao and Taiwan) were analyzed. The categories of BP were defined as normal BP (<120/80 mmHg), elevated BP [systolic BP (SBP) 120-130 and diastolic BP (DBP) <80 mmHg], and Stage 1 (SBP 130-139 or DBP 80-89 mmHg) and Stage 2 (SBP ≥140 or DBP ≥90 mmHg) hypertension. The prevalence and control of hypertension were estimated using a new definition, and the association between the main target organs' injury and new categories of BP was analyzed. RESULTS: The prevalence, awareness and treatment of hypertension in nondialysis CKD patients were 79.8, 72.4 and 68.3%, respectively. Approximately 11.9% had BP <130/80 mmHg and 6.6% had BP <120/80 mmHg. Subgroups by categories of BP had significant differences in age, sex, body mass index category, primary cause and CKD stage (P < 0.001). After multivariable adjustment, only Stage 2 hypertension was associated with decreased renal function [odds ratio (OR) 2.4, 95% confidence interval (CI) 1.9-3.0, P < 0.001], cardiovascular disease (OR 2.0, 95% CI 1.3-3.1, P = 0.001) and cerebrovascular disease (OR 2.7, 95% CI 1.2-5.8, P = 0.015). CONCLUSIONS: Using the new definition of hypertension, the higher prevalence and lower control of hypertension were shown in nondialysis CKD participants. More studies are necessary to confirm the applicability of new categories of BP in CKD population because only Stage 2 hypertension showed statistical association with the main target organs' injury.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Tang L, Zhang W, et al. Applying the new intensive blood pressure categories to a nondialysis chronic kidney disease population: the Prevalence, Awareness and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China survey. Nephrol Dial Transplant. 2020. PMID: 30304540. doi:10.1093/ndt/gfy301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。